Not available outside of the UK & Ireland.
Application
W146 hydrate has been used to assess vascular permeability in mice.
Biochem/physiol Actions
Potent S1P(1) competitive antagonist; Ki = 10-77 nM.
Features and Benefits
This compound is featured on the Lysophospholipid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
General description
W146 hydrate functions as an orthosteric antagonist. It is associated with blood lymphopenia and lung edema in mice.
Packaging
1, 5 mg in glass bottle
This product has met the following criteria to qualify for the following awards: